Neurogene (NGNE) News Today

Neurogene Inc. (NASDAQ: NGNE) shares have moved higher as analysts largely improved their longer-term outlook, although near-term earnings expectations remain mixed.

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $65 price target while raising its FY2027 EPS forecast to a loss of $4.99 per share from a projected loss of $5.92. The firm also lifted its estimates for the first three quarters of 2027, indicating expectations for reduced losses over time.
• Positive Sentiment: HC Wainwright increased its Q4 2026 EPS estimate to a loss of $1.20 from $1.37 and raised its Q1–Q4 2027 estimates to losses of $1.22, $1.24, $1.26 and $1.27, respectively. These revisions suggest improving operating expectations beyond 2026.
• Positive Sentiment: Canaccord Genuity lowered its price target to $166, but the revised target remains substantially above Neurogene’s recent trading level, potentially reinforcing the stock’s significant upside narrative. Canaccord Genuity Group Lowers Neurogene Price Target
• Neutral Sentiment: HC Wainwright lowered its FY2026 EPS estimate modestly to a loss of $5.44 from $5.39 and trimmed its Q3 2026 estimate to a loss of $1.36 from $1.34. Neurogene is still expected to remain unprofitable, with consensus full-year EPS at a loss of $5.63.
• Negative Sentiment: The company’s latest quarterly results missed analyst expectations, reporting a $1.53-per-share loss versus the $1.42 consensus estimate. Continued losses and the absence of current earnings make the stock highly dependent on clinical and development progress.

Overall, the analyst revisions are a modestly positive catalyst for NGNE: near-term forecasts worsened slightly, but longer-term estimates improved substantially and HC Wainwright retained its Buy rating. The stock remains volatile and speculative, with a beta of 1.70 and a wide 52-week trading range.